

**LETTER TO THE EDITOR**

DOI 10.1002/acr2.11438

**Antineutrophil cytoplasmic antibody,  
glomerulonephritis and inactivated SARS-CoV-2  
vaccine: comment on the article by Garcia et al**

*To the Editor:*

We would like to share our ideas on the article “[Clinical Images: Severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech’s inactivated SARS-CoV-2 vaccine](#)” (1). Garcia et al concluded that theirs was “the first report of AAV [adeno-associated virus] possibly triggered by an inactivated COVID-19 [coronavirus disease 2019] vaccine” (1). We agree that COVID-19 might induce adverse effects and AAV might be a possible problem. An important concern is regarding a possible confounding disorder that might induce AAV. For a COVID-19 vaccine recipient, it is possible that there might be a forgotten comorbidity. For example, dengue might exist in a COVID-19 vaccine recipient (2), and it is also a possible cause of AAV (3).

Author disclosures are available at <https://onlinelibrary.wiley.com/action/downloadSupplement?doi=10.1002%2Facr2.11438&file=acr211438-sup-0001-Disclosureform.pdf>.

Rujittika Mungmunpantipantip, PhD   
Private Academic Consultant  
Bangkok, Thailand  
Viroj Wiwanitkit, MD   
Dr DY Patil University  
Pune, India

1. Garcia DS, Martins C, da Fonseca EO, de Carvalho VCP, de Rezende RPV. Clinical Images: severe proteinase 3 antineutrophil cytoplasmic antibody glomerulonephritis temporally associated with Sinovac Biotech’s inactivated SARS-CoV-2 vaccine. *ACR Open Rheumatol* 2022;4:277–8.
2. Kebayoon A, Wiwanitkit V. Dengue after COVID-19 vaccination: possible and might be missed. *Clin Appl Thromb Hemost* 2021;27:1076029621104.
3. Kakoullis L, Parperis K, Papachristodoulou E, Panos G. Infection-induced myeloperoxidase specific antineutrophil cytoplasmic antibody (MPO-ANCA) associated vasculitis: a systematic review. *Clin Immunol* 2020;220:108595.